Evidence map›Paper›PMID 41904702›Full record

ArticleImmunoHorizons2026

PDLIM2 repression: a common mechanism in viral lung infection.

Feng Gao, Yongzheng W Chen, Steven D Shapiro, Gutian Xiao, Zhaoxia Qu

Abstract read
In one paragraph

Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Feng GaoDepartment of Immunology and Immune Therapeutics, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.ORCID 0000-0001-8764-1107
Yongzheng W ChenBridge Undergraduate Science (BUGS) Jr. Program, University of Southern California, Los Angeles, CA, United States.
Steven D ShapiroDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, 90033, CA, United States.
Gutian XiaoDepartment of Immunology and Immune Therapeutics, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Zhaoxia QuDepartment of Immunology and Immune Therapeutics, Hastings Center for Pulmonary Research, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.

Funding

Structural and molecular dissection of NF-kappaB regulation by the ubiquitin E3 ligase PDLIM2 in lung innate immunity and diseasesR01GM144890 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI QU, ZHAOXIA, XIAO, GUTIAN · 2022 to 2025
$2.1M
Mechanistic difference of NF-kappaB in lung physiology and tumorigenesisR01CA258614 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Zhaoxia Qu, GUTIAN XIAO · 2022 to 2026
$1.9M
PDLIM2 as a cancer and chemosensitizing targetR01CA172090 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIAO, GUTIAN · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA172090NCI NIH HHS R01 CA258614NIH HHS R01 GM144890
6 · The paper itself

Abstract

PDLIM2, a PDZ-LIM domain-containing protein expressed highest in the lung and immune cells, serves as a unique tumor suppressor and immune modulator, mainly by turning off the activation of the master transcription factors NF-κB and STAT3. While its role in cancer is established, the involvement of PDLIM2 in viral infection remains unclear. Here we analyzed public gene expression data of blood leukocytes, bronchoalveolar lavage cells, and lung tissues from uninfected healthy humans and those infected with the respiratory virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or influenza. We found that PDLIM2 expression was repressed by viral infection, and notably, this repression correlated with the severity of infectious diseases. Consistently, the expression level of PDLIM2 was negatively associated with NF-κB and STAT3 activity across a diverse range of cell types, such as macrophages, monocytes, neutrophils, T cells, alveolar type 1 and 2 epithelial cells, airway epithelial cells, and fibroblasts. Accordingly, cells with low PDLIM2 expression exhibited aberrant activation of signaling pathways essential for cellular functions and immune responses. These findings highlight PDLIM2 repression as a common mechanism underlying human viral infectious diseases and suggest PDLIM2 as a potential biomarker and therapeutic target for disease prognosis, prevention, and treatment.

Indexed as

COVID-19Influenza, HumanLIM Domain ProteinsLungMicrofilament ProteinsHumansNF-kappa BSARS-CoV-2Signal TransductionSTAT3 Transcription FactorLIM Domain ProteinsMicrofilament ProteinsNF-kappa BPDLIM2 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorinfluenzaNF-kBPDLIM2 repressionSARS-CoV-2viral lung infection

Identifiers

PMID41904702
PMCPMC13168810

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.